SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

SEC Comment Letter 0000000000-24-004979 to VACCINEX, INC. (VCNX) (CIK 0001205922) (VCNX)

VACCINEX, INC. (VCNX) (CIK 0001205922)
Date: May 2, 2024 · CIK: 0001205922 · Accession: 0000000000-24-004979

AI Filing Summary & Sentiment

File numbers found in text: 333-278968

Date
May 2, 2024
Author
Not clearly detected
Form
UPLOAD
Company
VACCINEX, INC. (VCNX) (CIK 0001205922)

Letter

United States securities and exchange commission logo May 2, 2024 Maurice Zauderer President and Chief Executive Officer Vaccinex, Inc. 1895 Mount Hope Avenue Rochester, New York 14620 Re:Vaccinex, Inc. Registration Statement on Form S-3 Filed April 26, 2024 File No. 333-278968 Dear Maurice Zauderer: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jimmy McNamara at 202-551-7349 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: William Intner

Show Raw Text
United States securities and exchange commission logo
May 2, 2024
Maurice Zauderer
President and Chief Executive Officer
Vaccinex, Inc.
1895 Mount Hope Avenue
Rochester, New York 14620
Re:Vaccinex, Inc.
Registration Statement on Form S-3
Filed April 26, 2024
File No. 333-278968
Dear Maurice Zauderer:
            This is to advise you that we have not reviewed and will not review your registration
statement.
            Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
            Please contact Jimmy McNamara at 202-551-7349 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:       William Intner